Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients
Reactive oxygen species (ROS) are molecules involved in signal transduction pathways
with both beneficial and detrimental effects on human cells. ROS are generated by many …
with both beneficial and detrimental effects on human cells. ROS are generated by many …
Myocardial protection and current cancer therapy: two opposite targets with inevitable cost
P Efentakis, I Andreadou, KE Iliodromitis… - International Journal of …, 2022 - mdpi.com
Myocardial protection against ischemia/reperfusion injury (IRI) is mediated by various
ligands, activating different cellular signaling cascades. These include classical cytosolic …
ligands, activating different cellular signaling cascades. These include classical cytosolic …
3-Methyl-6-nitroindazole in some aqueous co-solvent mixtures: Solubility determination, preferential solvation and solvent effect analysis
W Li, A Farajtabar, R Xing, Y Zhu, H Zhao… - The Journal of Chemical …, 2020 - Elsevier
The equilibrium solubility of 3-methyl-6-nitroindazole in co-solvent mixtures of acetonitrile
(1)+ water (2), ethanol (1)+ water (2) and n-propanol (1)+ water (2) is reported. Experiments …
(1)+ water (2), ethanol (1)+ water (2) and n-propanol (1)+ water (2) is reported. Experiments …
Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases
Y Yu, X Su, Q Qin, Y Hou, X Zhang, H Zhang… - Pharmacological …, 2020 - Elsevier
As transcriptional co-activators, Yes-associated protein (YAP) and transcriptional coactivator
with PDZ-binding motif (TAZ) can regulate cell proliferation, migration, differentiation, and …
with PDZ-binding motif (TAZ) can regulate cell proliferation, migration, differentiation, and …
Management of acute coronary syndrome in cancer patients: it's high time we dealt with it
F Luca, I Parrini, MG Abrignani, CM Rao… - Journal of Clinical …, 2022 - mdpi.com
Cancer patients have an increased risk of cardiovascular disease and, notably, a significant
prevalence of acute coronary syndrome (ACS). It has been shown that an elevated presence …
prevalence of acute coronary syndrome (ACS). It has been shown that an elevated presence …
Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: CardioOncology State-of-the-Art Review
S Parashar, N Akhter, E Paplomata, IY Elgendy… - Cardio Oncology, 2023 - jacc.org
Improvements in early detection and treatment of gynecologic malignancies have led to an
increasing number of survivors who are at risk of long-term cardiac complications from …
increasing number of survivors who are at risk of long-term cardiac complications from …
Arterial thrombosis in cancer: spotlight on the neglected vessels
ML Canale, I Bisceglia, C Lestuzzi, I Parrini - Anticancer …, 2019 - ar.iiarjournals.org
Cancer patients are at risk for both venous and arterial thrombotic events. Accumulating
evidence suggests a link between cancer and arterial thrombosis events. The …
evidence suggests a link between cancer and arterial thrombosis events. The …
Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management
L Jiang, L Ping, H Yan, X Yang, Q He… - Expert Opinion on Drug …, 2020 - Taylor & Francis
Introduction Vascular endothelial growth factor (VEGF) is a key target in cancer therapy.
However, cardiovascular safety has been one of the most challenging aspects of anti …
However, cardiovascular safety has been one of the most challenging aspects of anti …
Cardiovascular toxicities following the use of tyrosine kinase inhibitors in Hepatocellular Cancer Patients: A Retrospective, Pharmacovigilance Study
X Lai, Q Wan, S Jiao, X Sun, J Hu… - Expert Opinion on Drug …, 2024 - Taylor & Francis
ABSTRACT Background Cardiac adverse events (AEs) are common in tyrosine kinase
inhibitors (TKIs). This study explored the cardiac AEs of TKIs through the Food and Drug …
inhibitors (TKIs). This study explored the cardiac AEs of TKIs through the Food and Drug …
Relation between plasma trough concentration of pazopanib and progression-free survival in metastatic soft tissue sarcoma patients
MS Minot-This, P Boudou-Rouquette, A Jouinot… - Pharmaceutics, 2022 - mdpi.com
Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue
sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and …
sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and …